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A new QepA4 variant was detected in an O86:H28 ST156-fimH38 Escherichia
coli, showing a multidrug-resistance phenotype. PAβN inhibition of qepA4-harboring
transconjugant resulted in increase of nalidixic acid accumulation. The qepA4 and catA1
genes were clustered in a 26.0-kp contig matching an IncF-type plasmid, and containing
a Tn21-type transposon with multiple mobile genetic elements. This QepA variant is
worrisome because these determinants might facilitate the selection of higher-level
resistance mutants, playing a role in the development of resistance, and/or confer
higher-level resistance to fluoroquinolones in association with chromosomal mutations.
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INTRODUCTION
Quinolones are broad-spectrum antibiotics that have been used in medical practice for the
treatment of severe or resistant infections (Kim and Hooper, 2014). This class of antibiotics is fully
synthetic and used widely in both human and veterinary medicine.
Bacterial resistance to fluoroquinolones has emerged quickly and has conventionally been
attributed to chromosomally encoded mechanisms that allow the alteration of quinolone
targets (QRDR, quinolone resistance-determining regions): DNA gyrase and topoisomerase IV
(Jacoby et al., 2014). However, the discovery of plasmid-borne determinants has increased the
genetic background on the mechanisms of quinolone resistance, such as the plasmid-mediated
fluoroquinolone resistance (PMQR) determinants.
The qepA gene is a PMQR gene encoding a 14-transmembrane-segment eﬄux pump of the
major facilitator superfamily (MFS). Unlike other MFS eﬄux pumps that typically export various
antimicrobial agents and dyes, QepA shows substrate specificity directed to the fluoroquinolones
ciprofloxacin and norfloxacin (Jacoby et al., 2014; Rodríguez-Martínez et al., 2016).
QepA1 was described in Escherichia coli clinical isolates from Japan and Belgium in 2007
(Périchon et al., 2007; Yamane et al., 2007). Since then two new variants have been described:
QepA2, in a CTX-M-15-producing E. coli isolated from urine and blood samples of a patient
suffering from pyelonephritis, in France, in 2007 (Cattoir et al., 2008); and, more recently, QepA3,
in an Enterobacter aerogenes isolated in 2011 from wound pus of a patient admitted at a Chinese
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hospital (Wang et al., 2015). These QepA2 and QepA3 variants
differ from QepA1 by two (Ala99Gly and Val134Ile) and five
(Ala235Glu, Pro274Leu, Trp318Cys,Met372Lys, and Ala445Thr)
amino acids, respectively (Table 1).
Antibiotic resistance genes are frequently associated to
mobile genetic elements (MGE), such as insertion sequences
(ISs), phages, transposons and plasmids, which enhance their
ability to efficiently spread among different bacterial species
(Stokes and Gillings, 2011). The occurrence of MGE harboring
multiple antibiotic resistance genes is also frequent, and enables
the development of bacterial multidrug-resistance (MDR),
which may be responsible for therapeutic failures (Poirel
et al., 2012; Kim and Hooper, 2014). Indeed, PMQRs are
commonly described in isolates co-producing plasmid-mediated
β-lactamases (PMAβ) and extended-spectrum β-lactamases
(ESBL) (Jacoby et al., 2014).
In this study, we have identified and characterized the
fourth variant of the QepA determinant-QepA4, which is
responsible for the increased levels of resistance to clinically
important quinolones. Furthermore, this is also, at our
knowledge, the first description of the co-production of
QepA and both the PMAβ CMY-2 and the penicillinase
TEM-1. The study highlights the need of surveillance of this
resistance mechanism and reinforces a more careful use of
quinolones.
METHODS
Antibiotic Susceptibility Testing and
Molecular Characterization
Minimum inhibitory concentrations (MICs) of E. coli
INSRA6015 isolated from a Portuguese healthcare facility
were determined by microdilution and E-test methods according
to European Committee on Antimicrobial Susceptibility Testing
(EUCAST) guidelines (Table 2). Interpretation of the results was
done according to the EUCAST epidemiological cut-off values
(http://mic.eucast.org/Eucast2/). Detection and identification of
β-lactamase- and PMQR-encoding genes, as well as the analysis
of the quinolone-resistance-determining region (QRDR) was
performed as previously described (Jones-Dias et al., 2013).
TABLE 1 | Comparison of amino acid substitutions, and epidemiology of first reports of clinical QepA-producing strains.
PMQR gene Amino acid at position no. Straina Countryb References
95 99 134 235 274 318 372 445
qepA1 Phe Ala Val Ala Pro Trp Met Ala E. coli (unknown) Japan and Belgium (2007) Périchon et al., 2007;
Yamane et al., 2007
qepA2 Gly Ile E. coli (urine and blood) France (2008) Cattoir et al., 2008
qepA3 Glu Leu Cys Lys Thr E. coli (blood, and sputum),
C. koseri (sputum),
K. pneumoniae (blood),
E. cloacae (chest wound)
China (2015) Wang et al., 2015
qepA4 Leu Ile E. coli (urine) Portugal This study
aQepA-producing isolate, and respective human biological product of isolation (in parentheses), in the first report.
bCountry that first reported the PMQR, and year (in parenthesis).
Gene Transfer Experiments
In order to characterize the QepA4 determinant, transformants
were obtained by amplifying qepA4 with primers qepA-F
(5′–CGTTAAAGCATTCTTGTCCCGG–3′) and qepA-R (5′–
ATGTCCGCCACGCTCCACG–3′), cloning it in the pBK-
CMV phagemid vector (Stratagene), and transforming it
into TOP10 OneShot chemically competent E. coli cells
(Invitrogen). Susceptibility of transformants to an assortment
of fluoroquinolones was tested alone and in the presence
of 50µg/mL of the eﬄux pump inhibitor phenyl-arginine-β-
naphthylamide (PAβN) (Sigma-Aldrich) (Périchon et al., 2007),
as mentioned above (Table 2). EcTOP10 (pBK-qepA1) strain was
used as control.
Genomic Characterization of
QepA4-Producing E. coli
The QepA4-producing E. coli was characterized by whole-
genome sequencing (WGS), as previously described (Manageiro
et al., 2015). Briefly, genomic DNA was extracted using DNeasy
Blood and Tissue Kit (Qiagen) and quantified using Qubit
1.0 Fluorometer (Invitrogen). The Nextera XT DNA Sample
Preparation Kit (Illumina) was used to prepare sequencing
libraries from 1 ng of genomic DNA according to the
manufacturer’s instructions. WGS was performed using 150
bp paired-end reads on a MiSeq (Illumina). Sequence reads
were trimmed and filtered according to quality criteria, and
de novo assembled into contigs by means of CLC Genomics
Workbench 10.0 (QIAGEN). PathogenFinder 1.1, ResFinder
2.1, VirulenceFinder 1.4, SerotypeFinder 1.1, MLST 1.8, pMLST
1.4, and ISSaga were used to estimate the pathogenicity
determinants, acquired antibiotic resistance genes, virulence
factors, serotype, MLST, plasmid MLST, and insertion sequence
regions, respectively in the genomes of PMQR-producing E. coli
(Manageiro et al., 2015).
RESULTS AND DISCUSSION
INSRA6015 showed non-susceptibility to fluoroquinolones
(E-test method) and to third-generation cephalosporins,
aztreonam, and cefoxitin (microdilution method); no synergy
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with clavulanate was detected. The E. coli isolate remained
susceptible to piperacillin/tazobactam and imipenem (Table 2).
The β-lactamase-encoding genes blaTEM–1 and blaCMY–2, and
the PMQR-encoding gene qepA were detected by molecular
methods. Sequence analysis of the QepA variant showed amino
acid substitutions Phe95Leu and Val134Ile, justifying the new
name QepA4 (Table 1). Sequencing of QRDR revealed the
presence of three amino acid substitutions in the correspondent
proteins: Ser83Leu and Asp87Asn in GyrA subunit of DNA-
gyrase, and Glu84Lys in the ParC subunit of topoisomerase-
IV. These results are consistent with the detected high levels of
resistance to fluoroquinolones (MIC>32 mg/L) (Table 2).
EcTOP10 (pBK-qepA4) strain revealed susceptibility to all
fluoroquinolones and remaining antibiotics classes tested. In
fact, susceptibility levels were similar to the ones showed
by EcTOP10 (pBK-qepA1) strain, with exception of non-
susceptibility to norfloxacin (0.094 vs. 0.38 mg/L, respectively).
However, the qepA4-encoding transformant showed higher MIC
values to nalidixic acid (≥6-fold), ciprofloxacin (≥2-fold) and
norfloxacin (3-fold) than the qepA-negative strain. Moreover,
the levels of susceptibility to nalidixic acid upon QepA with
and without inhibition by PAβN were 3-fold higher for qepA4-
and qepA1-encoding transformants (Table 2). These results show
variability in the level of qepA expression, as previously discussed
(Rodríguez-Martínez et al., 2016).
WGS allowed the characterization of the qepA4 genetic
background. The analysis yielded 91 contigs (from 203 to 358,909
bp), with a minimum 64-fold coverage. The draft genome
contained a total assembly length of 4,770,076 bp, with a mean
coverage of about 160-fold; the GC content was 50.9%. All
de novo contigs were searched against the GenBank complete
plasmids database using Megablast, with 14/91 contigs mapping
against plasmid sequences therein deposited. Full details of these
contigs are available in Table 3.
The qepA4 gene was found in a 25,957 bp length contig, which
enclosed a composite mercury resistance Tn21-like transposon
(Figure 1), showing 99% identity with previously described
IncFII NR1 low-copy-number natural plasmid (Williams et al.,
2006), over 80% length coverage. The region located between
urf2 and tnpM (Figure 1A) was interrupted by a complete
In227 (Figure 1B), which included IS1353 inserted into IS1326,
thus interrupting tniB gene (Figure 1C). The variable region
harbored a 1dfrB4 and a qepA4 gene downstream of an ISCR3
element, which was flanked upstream by In211. Downstream
of the Tn21-like transposition region, two acetyltransferase
genes (catA1, ybjA) were detected. Unlike qepA1 or qepA3,
this qepA4 gene was not genetically associated to the rmtB
gene encoding a plasmid-mediated ribosomal methylase, which
is consistent with susceptibility to aminoglycosides showed by
INSRA6015. The remaining sequence of the contig matched
with previously described qepA-harboring IncFII plasmids,
such as pJJ1887-5 and pHN3A11, reported in the USA and
China, respectively (Chen et al., 2014; Johnson et al., 2016),
which correlates with PCR-based replicon results obtained
(Carattoli et al., 2005). Horizontal transfer of the qepA4
gene was not achieved either by bacterial conjugation or
through the direct transformation of plasmid DNA (data
TABLE 2 | MICs (mg/L) of antibiotics for the E. coli (Ec) strains: clinical
INSRA6015, EcTOP10 (pBK-qepA1), and EcTOP10 (pBK-qepA4) transformants,
and the recipient EcTOP10 (pBK-qepA−).
Antibiotic Ec INSRA6015
(qepA4, blaTEM–1,
blaCMY–2)
EcTOP10
(pBK-qepA−)
EcTOP10
(pBK-qepA1)
EcTOP10
(pBK-qepA4)
β-LACTAMSa
Amoxicillin 1,024 2 4 4
Amoxicillin + CLA 128 4 4 4
Ticarcillin >4,096 ≤0.125 4 4
Piperacillin 128 ≤0.015 1 1
Piperacillin + TAZ 4 ≤0.015 ≤0.015 ≤0.015
Mecillinam 1 ≤0.015 0.25 0.125
Cefuroxime 16 4 4 4
Ceftazidime 8 0.125 0.125 0.125
Ceftazidime + CLA 8 0.125 0.125 0.125
Ceftriaxone 8 0.03 0.03 0.03
Ceftriaxone + CLA 4 0.03 ≤0.015 ≤0.015
Cefotaxime 4 0.06 0.06 0.06
Cefotaxime + CLA 4 0.03 0.03 0.03
Cefoperazone 8 ≤0.25 ≤0.25 ≤0.25
Cefepime 0.125 ≤0.015 ≤0.015 ≤0.015
Cefoxitin 32 1 1 1
Aztreonam 4 0.06 0.06 0.06
Aztreonam + CLA 4 0.03 0.03 0.03
Imipenem 0.125 0.125 ≤0.06 0.125
OTHER CLASSESa
Kanamycin 2 ≤0.125 ≤0.125 ≤0.125
Trimetoprim >512 ≤0.125 ≤0.125 ≤0.125
QUINOLONESb
Nalidixic Acid >256 ≤0.015 1 0.75
Nalidixic Acid + PaβN – ≤0.015 0.125 0.125
Ciprofloxacin 1024 ≤0.002 0.016 0.007
Ciprofloxacin + PaβN – ≤0.002 0.006 ≤0.002
Enrofloxacin >32 ≤0.002 0.004 ≤0.002
Enrofloxacin + PaβN – ≤0.002 ≤0.002 ≤0.002
Gatifloxacin >32 ≤0.002 0.004 ≤0.002
Gatifloxacin + PaβN – ≤0.002 ≤0.002 ≤0.002
Levofloxacin >32 0.004 0.008 0.004
Levofloxacin + PaβN – ≤0.002 ≤0.002 ≤0.002
Moxifloxacin >32 ≤0.002 ≤0.002 ≤0.002
Moxifloxacin + PaβN – ≤0.002 ≤0.002 ≤0.002
Norfloxacin >256 0.016 0.38 0.094
Norfloxacin + PaβN – 0.016 0.19 0.094
Ofloxacin >32 0.008 0.016 0.012
Ofloxacin + PaβN – 0.004 0.004 0.003
–, Non determined.
aMICs determined by microdilution method.
bMICs determined by E-test.
PaβN, efflux pump inhibitor phenyl-arginine-β-naphthylamide at 50 µg/mL.
not shown), suggesting the presence of a non-transferable
plasmid.
Further analysis revealed the presence of genes conferring
resistance to β-lactams (blaTEM–1, blaCMY–2), tetracycline
[tet(B)], phenicol (catA1-type), sulphonamides (sul1) and
trimethoprim (dfrB4-type). CMY-2- and TEM-1-encoding genes
(LLKU01000025 and LLKU01000032 contigs, respectively),
contrarily to the other genes found, were not detected within
contigs that mapped against plasmid sequences (with ≥98% of
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TABLE 3 | Assembled contigs representing plasmids identified after BLASTn searched against the NCBI plasmid database.
Contigsa Resistance determinants Strain name Query
cover
(%)
Identity
(%)
Accession number
LLKU01000012 Escherichia coli strain FORC_031 plasmid pFORC31.1 100 100 NZ_CP013191.1
LLKU01000032 catA1-type Klebsiella pneumoniae subsp. pneumoniae KPX plasmid pKPX-1
DNA
100 100 NC_021198.1
LLKU01000037 Escherichia coli strain CH613_eco plasmid unnamed2 98 100 NZ_CM007909.1
LLKU01000042,
LKU01000051
Salmonella enterica subsp. enterica serovar Quebec str. S-1267
plasmid punamed2
100 98 NC_020278.2
LLKU01000044 qepA4 Escherichia coli strain 3A11 plasmid pHN3A11 100 99 NC_020278.2
Escherichia coli JJ1887 plasmid pJJ1887-5 NZ_CP014320.1
LLKU01000049 catA1-type, sul1, ∆dfrB4, mer operon,
ethidium bromide resistance protein
Escherichia coli strain CD306 plasmid pCD306 98 99 NZ_CP013832.1
LLKU01000055 catA1-type Escherichia coli plasmid pH2291-144 100 100 NC_025139.1
LLKU01000058 Salmonella enterica subsp. enterica serovar Senftenberg
NCTC10384, plasmid: 4
NZ_LN868946.1
Escherichia coli strain 207 plasmid unnamed NZ_CP019559.1
LLKU01000057,
LKU01000060
tet(B) Salmonella enterica subsp. enterica serovar Heidelberg strain
N13-01290 plasmid pN13-01290_23
100 100 NZ_CP012931.1
Escherichia fergusonii ATCC 35469 plasmid pEFER NC_011743.1
LLKU01000068 Escherichia coli UMNF18 plasmid pUMNF18_87 99 99 NZ_AGTD01000003.1
LLKU01000069 Citrobacter freundii strain 705SK3 plasmid p705SK3_1 100 100 NZ_CP022152.1
Escherichia coli strain EC1515 plasmid pEC1515-2 NZ_CP021846.1
LLKU01000073 Escherichia coli JJ1887 plasmid pJJ1887-5 100 100 NZ_CP014320.1
Only the best BLASTn hit(s) reference plasmid sequence is shown (e value = 0.0, query cover ≥ 98% and identity ≥ 98%).
aContigs underlined includes the resistance determinants.
query coverage and ≥98% of identity) (Table 3). According with
the methodology used, the strain does not have other typeable
plasmids.
Overall, 53 putative ORFs related to ISs were found within the
INSRA6015 genome: 21 complete, 28 partial, and 4 uncategorized
(including IS1, IS1380, IS21, IS3ssgrIS3, ISAs1, and Tn3 with
100% of similarity with those described in the ISsaga database.
Three virulence factors (iss, lpfA, gap) were identified. Moreover,
this O86:H28 E. coli isolate displayed a prediction of 93.4%
for being a human pathogen, based on the probability scores
assigned by PathogenFinder.
In addition, QepA4-producing E. coli presented a set
of genetic features crucial to support their own successful
dissemination (Figure 1), such as multiple antibiotic resistance
genes carried by MGE, virulence factors and numerous other
pathogenicity factors. These features enlarge bacteria ability
for transboundary dissemination among bacteria from different
environments (Stokes and Gillings, 2011; Caniça et al., 2015).
The QepA4-producing INSRA6015 E. coli isolate belonged to
the ST156 lineage (UCC scheme) and ST119 (Pasteur scheme),
and showed the fimH38 allele upon fimH typing. This ST has been
reported associated with different antibiotic-resistance genes,
namely PMAβ and ESBL, NDM carbapenemases, and 16S rRNA
methylases, both in clinical and colonizing human-associated E.
coli isolates collected in different countries, and in water samples
from Bangladesh (Corvec et al., 2010; Mushtaq et al., 2011; Pan
et al., 2013; Sáez-López et al., 2014; Rashid et al., 2015). Indeed,
the qepA4 variant identified in this clinical isolate matched
a partial QepA-type sequence (Accession Number LK934678)
detected in a TEM-1 and CTX-M-15-producing E. coli strain
recovered in a raw wastewater sample in Portugal, but from a
different ST (ST443) (Varela et al., 2015).
The PMQR determinants confer low-level quinolone
resistance that, in some cases, does not exceed the clinical
breakpoint for susceptibility as demonstrated in this study
and by others (Jacoby et al., 2014). However, its presence may
facilitate higher-level resistance under selective pressure
from antimicrobial agents at therapeutic levels, mostly
due to chromosomal mechanisms, which makes infection
by pathogens containing PMQR harder to treat (Poirel
et al., 2012). Fortunately, the qepA4 gene detected in this
study was not in a genetic linkage to rmtB gene as has
been demonstrated; this suggests that are no potential
for selection of the QepA4 determinant by the use of
aminoglycosides.
CONCLUSION
In conclusion, qepA4 was here first identified in an rmtB-
negative clinical isolate, and genetically characterized within a
composite mercury resistance Tn21-like transposon, harboring
other different mobile genetic elements. This report represents
an important finding about a plasmid-mediated resistance
mechanism, which contributes with other quinolone resistance
mechanisms to increase therapeutic failures, and understanding
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FIGURE 1 | Schematic representation of qepA4-harboring contig assembled using LLKU01000032, LLKU01000034, LLKU01000049, and LLKU01000073, with
mean coverage of 134-fold and 59.0% of GC content. (A) The Tn21-like transposon included the transposition (tnp) region [comprising the transposase (tnpA), the
resolvase (tnpR), and the putative transposition regulator (tnpM)]; the resolution site (res); and the mercury resistance (mer) operon [with the regulatory genes merR
and merD, the structural genes merT, merP, merC, and merA, and two unknown reading frames: urf1 (also called merE) and urf2, downstream of merD]; (B) The urf2
gene was interrupted by a complete In227 integron, which variable region (vr) harbored a 1 dfrB4 and a qepA4 gene downstream an ISCR3 element, flanked
upstream by an In211 integron; (C) Two ISs (IS1353 inserted into IS1326) interrupted the tniB (transposition of the integron) gene. IR, flanking inverted repeats; oriIS
and terIS, origin and terminus of ISCR elements, respectively; vertical bars indicate IR of transposons (Tn), integrons (In) and insertion sequences (IS). Arrows indicate
the direction of transcription of the various genes. Truncated genes are indicated by a ∆ symbol.
of this resistance in different reservoirs (Poirel et al., 2012; Yan
et al., 2017).
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